Technology Networks
| ||
| Permissions | ||
|
Permission to use, copy and distribute documents presented on this World Wide Web site and related graphics is not granted without prior written permission of Technology Networks Ltd
To obtain this permission contact:
In cases where permission is granted, it is done so under the provision that the above copyright notice and this permission notice appear in all copies. All other rights are reserved. |
Promethera Biosciences Treats First Patients with Promethera® HepaStem
Phase I/II study designed to evaluate the ability of liver progenitor cells to restore a missing enzyme function in liver-based metabolic diseases. Mucosis Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans Mimopath®-based vaccines are able to produce balanced immune responses in both circulating blood and the respiratory tract. New Muscular Dystrophy Treatment Approach Developed Using Human Stem Cells New process makes the production of human muscle cells from stem cells efficient and effective. Mucosis Announces Publication of Preclinical Data of Novel Influenza Vaccines Mucosally administered Mimopath-based influenza vaccine protects against both homologous and heterologous challenge. Idera Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial IMO-2055 to be used in treatment of patients with advanced head and neck cancer. Agent Reduces Autism-like Behaviors in Mice Boosts sociability, quells repetitiveness - NIH study. Adocia Reports Positive Phase II Clinical Results for the Treatment of Diabetic Foot Ulcer Adocia’s spray formulation of PDGF-BB, combined with BioChaperone®, has been evaluated versus Regranex®, gel of PDGF-BB. New Classification Criteria Released for Research on Sjogren's Syndrome NIH-supported alliance validates classification criteria for condition based on objective tests. NIH Study to Test Treatment for Fatty Liver Disease in Children NIH researchers to find out fatty liver disease diagnosis with cysteamine in CyNCh trial. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat Drug studied in combination with Lapatinib in HER2-positive metastatic breast cancer. 
| |
